Terpene Biosynthesis in Cannabis
How cannabis plants build the volatile molecules behind their smell, from plastid pathways to glandular trichomes.
Terpene biosynthesis is one of the few areas of cannabis science with genuinely solid chemistry behind it. We know the pathways, we've cloned many of the enzymes, and we can map most major aromas to specific terpene synthases. What we don't know nearly as well is how those terpenes shape the human experience of a given cultivar. Treat the biochemistry as established; treat 'entourage' claims built on top of it with more skepticism.
What terpene biosynthesis is
Terpenes are a large family of hydrocarbons built from five-carbon isoprene units. In cannabis, as in other plants, every terpene ultimately derives from two universal C5 building blocks: isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP) [1][2]. These are condensed head-to-tail by prenyltransferases into longer prenyl diphosphates — geranyl diphosphate (GPP, C10) for monoterpenes, farnesyl diphosphate (FPP, C15) for sesquiterpenes, and geranylgeranyl diphosphate (GGPP, C20) for diterpenes [1].
Those prenyl diphosphates are then handed off to terpene synthases (TPSs), the enzymes that do the interesting chemistry: they ionize the substrate and guide it through a series of carbocation rearrangements, cyclizations, and quenching steps to produce a specific terpene skeleton [1][3]. A single TPS can often make several products from one substrate, which is part of why cannabis chemotypes are messier than marketing suggests. Strong evidence
The two pathways feeding the pool
Plants run two parallel pathways to make IPP and DMAPP, and cannabis is no exception [2][4]:
- MEP pathway (methylerythritol phosphate), located in plastids. It starts from pyruvate and glyceraldehyde-3-phosphate and primarily feeds monoterpenes (C10, e.g. myrcene, limonene, pinene) and the C20 precursors used for cannabinoid biosynthesis via GPP and its prenyl side chain [2][4].
- MVA pathway (mevalonate), located in the cytosol. It starts from acetyl-CoA and primarily feeds sesquiterpenes (C15, e.g. β-caryophyllene, humulene) [2][4].
There is some crosstalk between compartments — IPP can move across the plastid membrane — but in practice the monoterpene vs. sesquiterpene split tracks the MEP/MVA split reasonably well [2][4]. Notably, the prenyl side chain of cannabinoids (the geranyl group attached to olivetolic acid to make CBGA) also comes from the MEP pathway via GPP, which means cannabinoid and monoterpene biosynthesis compete for the same precursor pool [5]. Strong evidence
Where it happens: glandular trichomes
Cannabis terpene and cannabinoid biosynthesis is concentrated in glandular trichomes on female inflorescences and surrounding bracts, especially the capitate-stalked trichomes [5][6]. These are the resinous heads visible to the naked eye. Transcriptomic studies have shown that trichome secretory cells express terpene synthase genes and cannabinoid pathway genes at far higher levels than leaf or stem tissue [5][6].
The secreted terpenes accumulate in an extracellular storage cavity along with cannabinoids in their acidic forms. Because terpenes are volatile, a substantial fraction is lost during drying, curing, and storage — particularly the lighter monoterpenes — which is why fresh flower smells different from year-old flower and why extract chemistry rarely matches flower chemistry one-to-one [7]. Strong evidence
Cannabis terpene synthases
Functional characterization of cannabis TPSs accelerated in the 2010s. Booth, Page, and Bohlmann (2017) cloned and biochemically characterized a set of cannabis terpene synthases and assigned specific products to specific enzymes — for example, a (-)-limonene synthase, a β-myrcene synthase, an (E)-β-ocimene synthase, and a (-)-α-pinene synthase among the monoterpene producers, and several sesquiterpene synthases including a β-caryophyllene/α-humulene synthase [3]. A follow-up paper expanded the catalog and linked enzyme repertoire to chemotype differences between cultivars [8].
A few useful takeaways from that work:
- Most cannabis TPSs are multi-product enzymes. A single 'myrcene synthase' typically also makes minor amounts of other monoterpenes [3].
- Differences in cultivar aroma are driven both by which TPS genes are present/expressed and by substrate availability from the MEP and MVA pathways [3][8].
- The 'indica vs. sativa' label has essentially no predictive relationship to terpene profile at the chemistry level; chemotyping by GC-MS is far more informative [9]. Strong evidence
Why this matters for effects (and why to be careful)
The biochemistry above is well established. The leap from 'this strain has 0.8% myrcene' to 'this strain will make you couch-locked' is not. Most claims about terpene-driven effects in cannabis rely on:
- In vitro receptor binding assays (often at concentrations far above what flower delivers),
- Rodent behavioral studies with pure terpenes,
- Or extrapolation from aromatherapy literature.
Controlled human trials testing specific terpene profiles in inhaled cannabis are rare, and the ones that exist have generally not found large, reliable effects attributable to terpenes independent of THC and CBD content [10]. The popular 'myrcene above 0.5% means couch-lock' rule, in particular, has no published primary source and should be treated as folklore No data.
This doesn't mean terpenes are irrelevant — they clearly drive aroma, almost certainly shape subjective character, and some (notably β-caryophyllene) have documented pharmacology of their own Weak / limited. It means the chemistry is ahead of the clinical evidence, and honest writing should reflect that gap.
Cultivars and chemotypes
Rather than 'strains dominant in this terpene' (since this article covers the pathway, not a single terpene), it's worth noting that lab data on thousands of commercial samples cluster into a small number of recurring terpene chemotypes, regardless of strain name [9]:
- Myrcene-dominant (often with pinene or limonene secondary) — the most common chemotype in North American flower.
- Limonene-dominant (often with caryophyllene).
- Terpinolene-dominant (the classic 'Jack Herer / Haze' signature).
- Caryophyllene-dominant sesquiterpene profiles, sometimes with humulene.
The same name from different growers can land in different clusters, which is consistent with what we know about TPS expression being sensitive to genetics, light, nutrition, and harvest timing [8][9].
Related terpenes and topics
For the major individual terpenes whose biosynthesis is described above, see Myrcene, Limonene, Beta-Caryophyllene, Alpha-Pinene, Linalool, Humulene, and Terpinolene. For the parallel cannabinoid pathway that shares GPP with monoterpene biosynthesis, see Cannabinoid Biosynthesis. For the structures that house this chemistry, see Glandular Trichomes.
Sources
- Peer-reviewed Chen F, Tholl D, Bohlmann J, Pichersky E. (2011). The family of terpene synthases in plants: a mid-size family of genes for specialized metabolism that is highly diversified throughout the kingdom. The Plant Journal, 66(1), 212–229.
- Peer-reviewed Vranová E, Coman D, Gruissem W. (2013). Network analysis of the MVA and MEP pathways for isoprenoid synthesis. Annual Review of Plant Biology, 64, 665–700.
- Peer-reviewed Booth JK, Page JE, Bohlmann J. (2017). Terpene synthases from Cannabis sativa. PLOS ONE, 12(3), e0173911.
- Peer-reviewed Lichtenthaler HK. (1999). The 1-deoxy-D-xylulose-5-phosphate pathway of isoprenoid biosynthesis in plants. Annual Review of Plant Physiology and Plant Molecular Biology, 50, 47–65.
- Peer-reviewed Andre CM, Hausman J-F, Guerriero G. (2016). Cannabis sativa: The plant of the thousand and one molecules. Frontiers in Plant Science, 7, 19.
- Peer-reviewed Livingston SJ, Quilichini TD, Booth JK, et al. (2020). Cannabis glandular trichomes alter morphology and metabolite content during flower maturation. The Plant Journal, 101(1), 37–56.
- Peer-reviewed Ross SA, ElSohly MA. (1996). The volatile oil composition of fresh and air-dried buds of Cannabis sativa. Journal of Natural Products, 59(1), 49–51.
- Peer-reviewed Booth JK, Yuen MMS, Jancsik S, et al. (2020). Terpene synthases and terpene variation in Cannabis sativa. Plant Physiology, 184(1), 130–147.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. (2022). The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE, 17(5), e0267498.
- Peer-reviewed Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.